Brainstorm Cell Therapeutics Inc
Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modula… Read more
Brainstorm Cell Therapeutics Inc (BCLI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.341x
Based on the latest financial reports, Brainstorm Cell Therapeutics Inc (BCLI) has a cash flow conversion efficiency ratio of -1.341x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.10 Million) by net assets ($822.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Brainstorm Cell Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Brainstorm Cell Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Brainstorm Cell Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Brainstorm Cell Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KR Motors Co. Ltd.
KO:000040
|
-0.076x |
|
GigaMedia Limited
F:GIFN
|
N/A |
|
VL E-Governance & IT Solutions Limited
NSE:VLEGOV
|
N/A |
|
Manganese X Energy Corp
OTCQB:MNXXF
|
-0.220x |
|
Valtecne S.p.A.
F:71W
|
N/A |
|
NFL BIOSCIENCES EO -03
F:82F
|
N/A |
|
ezCaretech Co. LTD
KQ:099750
|
0.190x |
|
TDH Holdings Inc
NASDAQ:PETZ
|
0.010x |
Annual Cash Flow Conversion Efficiency for Brainstorm Cell Therapeutics Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Brainstorm Cell Therapeutics Inc from 2001 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.76 Million | $-9.09 Million | 1.171x | -72.19% |
| 2023-12-31 | $-4.86 Million | $-20.46 Million | 4.211x | -34.28% |
| 2022-12-31 | $-3.02 Million | $-19.32 Million | 6.408x | +571.89% |
| 2021-12-31 | $19.34 Million | $-26.27 Million | -1.358x | -36.84% |
| 2020-12-31 | $35.46 Million | $-35.19 Million | -0.992x | -207.85% |
| 2019-12-31 | $-12.22 Million | $-11.25 Million | 0.920x | +137.26% |
| 2018-12-31 | $5.02 Million | $-12.39 Million | -2.470x | -514.29% |
| 2017-12-31 | $5.88 Million | $-2.36 Million | -0.402x | +32.04% |
| 2016-12-31 | $9.90 Million | $-5.86 Million | -0.592x | -12.83% |
| 2015-12-31 | $14.13 Million | $-7.41 Million | -0.524x | +22.00% |
| 2014-12-31 | $6.67 Million | $-4.49 Million | -0.672x | +54.58% |
| 2013-12-31 | $2.74 Million | $-4.05 Million | -1.480x | -110.85% |
| 2012-12-31 | $4.15 Million | $-2.92 Million | -0.702x | +53.01% |
| 2011-12-31 | $1.49 Million | $-2.22 Million | -1.494x | -133.14% |
| 2010-12-31 | $-459.00K | $-2.07 Million | 4.508x | +956.02% |
| 2009-12-31 | $-1.74 Million | $-744.00K | 0.427x | -48.90% |
| 2008-12-31 | $-2.08 Million | $-1.73 Million | 0.835x | +14.32% |
| 2007-12-31 | $-2.43 Million | $-1.77 Million | 0.731x | +55.17% |
| 2006-12-31 | $-1.82 Million | $-855.00K | 0.471x | +197.46% |
| 2005-12-31 | $-7.91 Million | $-1.25 Million | 0.158x | +116.45% |
| 2004-12-31 | $704.45K | $-677.84K | -0.962x | -295.97% |
| 2003-12-31 | $-31.44K | $-15.44K | 0.491x | +242.56% |
| 2002-12-31 | $20.36K | $-7.01K | -0.344x | -141.49% |
| 2001-12-31 | $52.16K | $-7.44K | -0.143x | -- |